
AstraZeneca’s chief executive David Brennan is coming under increasing pressure from investors, and his future at the firm could be …
Merck has teamed up with catalyst specialist Codexis to develop a more efficient manufacturing process for recently-approved hepatitis C treatment …
A first-in-class test for Alzheimer’s disease has been approved by the FDA, but its makers have stressed its limitations.Lilly’s Amyvid …

Novo Nordisk is now able to claim superiority for its diabetes drug Victoza compared to Merck’s rival treatment Januvia.The US …
Johnson & Johnson has announced that Sheri McCoy, vice chairman of the executive committee, will leave the company on April …
The MHRA has announced procedural changes concerning the requirement to submit full-colour mock-ups of labels and patient leaflets for medicinal …

Pfizer’s heart pill Inspra has gained a new licence in the UK to reduce the risk of death in patients …

Roche is to sponsor a Twitter-based site devoted talk about diabetes, furthering its close links with online commentators. ‘Diabetes Nest’ …

Concerns about the growing number of companies disinvesting from neuroscience research have been growing in recent years, and the latest …
Dr Eric Abadie has told the European Medicines Agency that he is resigning as chair of the Committee for Medicinal …
The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …
Pharmaceutical manufacturers are acting ‘prematurely’ when asking excipient suppliers to provide metal impurity levels, according to a new position paper …

Swiss contract manufacturer and ingredients supplier Lonza has appointed Richard Ridinger as its new chief executive, replacing Stefan Borgas who …
AstraZeneca has bought its way into Amgen’s inflammation portfolio with a $50 million upfront payment to co-develop and commercialise five …
Orphan Medicinal Products in the EU: Eligibility, Orphan Designation and IncentivesThe structure of this webinar is:Introduction: Legislative Basis and Criteria …

The NHS in England spent less on its drugs budget last year, bucking the longstanding upward trend. This is because …

GlaxoSmithKline has insisted its new long-acting Type 2 diabetes drug albiglutide remains on course for filing following topline results from …
A new chair and vice-chair have been appointed to lead the European Medicines Group (EMG). EMG is the voice of …
Summit, a UK drug discovery company, has appointed Glyn Edwards as its new chief executive. Edwards will take up the …
The European Medicines Agency has introduced new rules to tighten up conflicts of interest, and have less reliance on pharma …